MED19

Across TCGA pan-cancer cohorts, MED19 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MED19 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MED19 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MED19 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where MED19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	1.000	0.464	<.001	34	view →
PDAC	DFS	Median	All	0.887	0.402	.006	21	view →
LSCC	OS	Tertile	II,III,IV	0.944	0.636	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MED19–CCRCC (OS)

Open the CCRCC breakdown →